OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
OS Therapies Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.27−0.05 (-3.79%)
Close on Oct 19, 2026
- Market cap
- $55.76M
- P/E (TTM)
- –
- Dividend yield
- –
OS Therapies Inc revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | YoY |
|---|---|---|---|---|
| CODM [Member] | -$28.71M | -$6.81M | – | +321.3% |
| Operating Segment [Member] | – | -$6.81M | -$4.34M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of OS Therapies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.